Selpercatinib and capmatinib combination promotes sustained complete response in novel fusion lung cancer after resistance to inhibitor via amplification: Case Report.

fusions occur in 1-2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective inhibitors with significant improvement of outcome in patients with tumor harboring fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary mutations, or in 5% via amplification. Co-inhibition of and is a compelling strategy for overcoming -dependent resistance to inhibitors and potentially other inhibitors.

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.

Background: Non-metastatic castration resistant prostate cancer (M0 CRPC) has seen important developments in drugs and diagnostic tools in the last two years. New hormonal agents have demonstrated improvement in metastasis free survival in M0 CRPC patients and have been approved by regulatory agencies in Brazil. Additionally, newer and more sensitive imaging tools are able to detect metastasis earlier than before, which will impact the percentage of patients staged as M0 CRPC.

Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

Prostate cancer is a significant burden and cause of mortality in Latin America. This article reviews the treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) and provides consensus recommendations to assist Latin American prostate cancer specialists with clinical decision making. A multidisciplinary expert panel from Latin America reviewed the available data and their individual experience to develop clinical consensus opinions for the use of life-prolonging agents in mCRPC, with consideration given to factors influencing patient selection and treatment monitoring.